SteadyMed Therapeutics

Device for Ongoing Delivery of Injectable Drugs

Health Tech & Life Sciences
Acquired (Inactive) by United Therapeutics Corporation on Apr 2018 - closed due to acquisition
Follow

Company Overview

Snapshot

Founded in June 2005 by Ian Solomon, SteadyMed Therapeutics operated with 1–10 employees. The company raised a total of $126.6 million across 7 funding rounds from 8 investors. In April 2018, SteadyMed Therapeutics was acquired by United Therapeutics Corporation.

Business overview

SteadyMed Therapeutics Inc. developed the PatchPump platform, a proprietary ECell technology for the ongoing delivery of injectable drugs. This customizable, prefilled, preprogrammed, and disposable parenteral delivery system is designed for large-volume and viscous formulations. The device attaches to the abdomen to deliver medicine through a small needle. SteadyMed initially focused on serving patients with pulmonary arterial hypertension and chronic pain, operating within the Health Tech & Life Sciences sector, specifically in Drug Delivery.

Strategic signal

In April 2018, SteadyMed Therapeutics was acquired by United Therapeutics Corporation. This acquisition highlights the strategic value of SteadyMed's PatchPump platform in the drug delivery market, signaling a consolidation trend within the pharmaceutical industry for innovative delivery technologies.

Log in to access full profile ›

Company Intelligence Q&A

What is SteadyMed Therapeutics' primary focus?
SteadyMed Therapeutics focuses on developing and commercializing the PatchPump platform, a device for the ongoing delivery of injectable drugs, particularly for conditions like pulmonary arterial hypertension and chronic pain.
When was SteadyMed Therapeutics acquired?
SteadyMed Therapeutics was acquired by United Therapeutics Corporation in April 2018.
Which investors participated in SteadyMed Therapeutics' April 2017 funding round?
In April 2017, SteadyMed Therapeutics received funding from investors including.
What was a significant financial milestone for SteadyMed Therapeutics in March 2015?
In March 2015, SteadyMed Therapeutics completed an Initial Public Offering on NASDAQ.
Who were the investors in SteadyMed Therapeutics' September 2012 funding round?
In September 2012, SteadyMed Therapeutics secured funding from investors including.
Log in to access full profile ›

External links